ArticleTheranostics2021
Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response.
Article in Theranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 42 citations in OpenAlex.
- In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy.European journal of nuclear medicine and molecular imaging · 2022Trial
- Context-dependent efficacy of fibroblast activation protein-targeted radionuclide therapy (FAP-TRT): the dual role of CAFs.European journal of nuclear medicine and molecular imaging · 2026Article
- Immune Checkpoint Blockade Enhances the Abscopal Effect of [European journal of nuclear medicine and molecular imaging · 2026Article
- From uniform to heterogeneous dose models: connecting cellular and tumor absorbed dose-response for [European journal of nuclear medicine and molecular imaging · 2026Article
- Evaluating the impact of Lutetium-177 therapy on bioprosthetic heart valves in carcinoid heart disease.Cardio-oncology (London, England) · 2026Article
- Comparing Response Evaluation Methods for PRRT in Neuroendocrine Tumors: Insights from an Exploratory Study.Cancers · 2026Article
- Investigation of MicroRNAs as predictors of radioligand therapy response in gastroenteropancreatic neuroendocrine tumours.Scientific reports · 2026Article
- Radiocopper in BCMA-targeted immunotheranostics of myeloma.Theranostics · 2026Article
- Dose-Dependent Cellular Phenotypic Change Induced byBiomedicines · 2025Article
- New Horizons: The Evolution of Nuclear Medicine in the Diagnosis and Treatment of Pancreatic Neuroendocrine Tumors-A Case Report.Journal of clinical medicine · 2025Article
- Full-Body Tumor Response Heterogeneity of Metastatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radiopharmaceutical Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Organ-specific response to [Endocrine · 2025Article
- Article
- Predicting the Response of Patients Treated withJournal of medical signals and sensors · 2024Article
- Low-dose targeted radionuclide therapy synergizes with CAR T cells and enhances tumor response.Frontiers in immunology · 2024Article
- The heterobivalent (SSTR2/albumin) radioligand [Theranostics · 2024Article
- Review
- In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib.Cancers · 2023Article
- DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapyTheranostics · 2023Article
- Imaging DNA damage response by γH2AXTheranostics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with neuroendocrine tumors (NETs) can be treated with peptide receptor radionuclide therapy (PRRT). Here, the somatostatin analogue octreotate radiolabeled with lutetium-177 is targeted to NET cells by binding to the somatostatin receptor subtype 2 (SST
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.